Clinical Trial Update: A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial of GSK2140944 for uncomplicated urogenital gonorrhea completed with results posted in 2017, assessing efficacy, safety, and tolerabil…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gonorrhea

Drugs mentioned

• GSK2140944

Snippet

Sponsor: GlaxoSmithKline | Conditions: Gonorrhea | Phase 2 | Status: COMPLETED | Results posted: 2017-05-23